Reference
·Primary source
Government Pharmaceutical Organisation (GPO) state procurement
~THB 18-20B (2024)
The Government Pharmaceutical Organisation (GPO), Thailand's state-owned pharmaceutical manufacturer and procurement agency, recorded approximately THB 18-20 billion in revenue in 2024 per Ministry of Public Health disclosure, anchored by state procurement contracts for the Universal Coverage Scheme, Civil Servant Medical Benefit Scheme, and Social Security Scheme. GPO manufactures roughly 200-250 generic formulations in-house at Pathum Thani and Rangsit facilities, and procures the residual via tender from PReMA-member multinationals and local generics manufacturers. The agency's pricing benchmarks materially anchor Thailand's national drug reimbursement schedule.
Figure in context
The Government Pharmaceutical Organisation (GPO), Thailand's state-owned pharmaceutical manufacturer and procurement agency, recorded approximately THB 18-20 billion in revenue in 2024 per Ministry of Public Health disclosure, anchored by state procurement contracts for the Universal Coverage Scheme, Civil Servant Medical Benefit Scheme, and Social Security Scheme. GPO manufactures roughly 200-250 generic formulations in-house at Pathum Thani and Rangsit facilities, and procures the residual via tender from PReMA-member multinationals and local generics manufacturers. The agency's pricing benchmarks materially anchor Thailand's national drug reimbursement schedule.
The Government Pharmaceutical Organisation (GPO), Thailand's state-owned pharmaceutical manufacturer and procurement agency, recorded approximately THB 18-20 billion in revenue in 2024 per Ministry of Public Health disclosure, anchored by state procurement contracts for the Universal Coverage Scheme, Civil Servant Medical Benefit Scheme, and Social Security Scheme. GPO manufactures roughly 200-250 generic formulations in-house at Pathum Thani and Rangsit facilities, and procures the residual via tender from PReMA-member multinationals and local generics manufacturers. The agency's pricing benchmarks materially anchor Thailand's national drug reimbursement schedule.
Time scope
FY2024
Source basis
Primary source
Interpretation notes
What this tells you
The Government Pharmaceutical Organisation (GPO), Thailand's state-owned pharmaceutical manufacturer and procurement agency, recorded approximately THB 18-20 billion in revenue in 2024 per Ministry of Public Health disclosure, anchored by state procurement contracts for the Universal Coverage Scheme, Civil Servant Medical Benefit Scheme, and Social Security Scheme. GPO manufactures roughly 200-250 generic formulations in-house at Pathum Thani and Rangsit facilities, and procures the residual via tender from PReMA-member multinationals and local generics manufacturers. The agency's pricing benchmarks materially anchor Thailand's national drug reimbursement schedule.
What not to do with it
GPO procurement underpins the Universal Coverage Scheme drug benefit. Pricing is below private distribution channel by 30-50% for equivalent generics.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand pharmaceutical distribution and wholesale revenue (2020-2024)
Pharmaceutical Research and Manufacturers Association, Ministry of Public Health Drug Information Center, Thai FDA
Thailand pharmaceutical distributor market share (2024)
DKSH Group investor disclosures, Zuellig Pharma corporate filings, PReMA member surveys
Thailand pharmacy chain store count (2020-2024)
Boots Thailand corporate disclosures, Watsons CK Hutchison investor materials, Pharmacy Council of Thailand registry
DKSH Thailand healthcare segment revenue (2020-2024)
DKSH Group annual reports, DKSH Q4 trading updates, SIX Swiss Exchange disclosures
Thai FDA new drug registration approvals (2020-2024)
Thai Food and Drug Administration annual report, Ministry of Public Health, PReMA regulatory tracking
Thailand pharmaceutical cold-chain share of distribution
PReMA cold-chain working group, DKSH Thailand healthcare disclosure, Thai FDA Good Distribution Practice guidance
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.